文献速递血栓与止血

Jmjd1c介导的表观遗传调控自身免疫与HIT抗体产生

Jmjd1c-mediated epigenetic control of autoimmunity and HIT antibody production.
PubMed 文献 · Blood · 2026-01-01

本研究探讨表观遗传修饰在肝素诱导的血小板减少症(HIT)中的作用。发现Jmjd1c缺失破坏免疫耐受,促进包括PF4/肝素特异性血小板激活抗体在内的自身反应性抗体产生,且HIT患者B细胞转录谱与Jmjd1c缺陷B细胞高度重叠,揭示表观遗传机制参与HIT发病。

要点

  • Jmjd1c是PF4/肝素特异性抗体产生的关键调节因子。
  • Jmjd1c缺陷B细胞BCR诱导的增殖增强,H3K36me1修饰增加。
  • HIT患者B细胞BCR信号、NF-κB等通路富集,与Jmjd1c缺陷B细胞相似。

核心结论

  • Jmjd1c缺陷破坏免疫耐受并促进自身反应性抗体产生,与人类HIT B细胞存在分子重叠,首次将表观遗传调控与HIT发病联系起来。

研究设计与样本

  • 研究采用Jmjd1c缺陷小鼠模型及HIT患者B细胞,进行转录组RNA测序和CUT&Tag分析。

主要发现

  • Jmjd1c在B细胞发育中表达但对正常B细胞发育非必需,其缺陷导致B细胞对BCR刺激高反应性。
  • RNA测序显示Jmjd1c缺陷B细胞中BCR信号、NF-κB激活、细胞周期和SLE相关通路上调。
  • CUT&Tag显示Jmjd1c缺陷增加这些通路基因起始位点的H3K36me1修饰。
  • HIT患者B细胞转录谱和调节子分析富集BCR信号、细胞周期、NF-κB和SLE相关通路,与Jmjd1c缺陷B细胞高度相似。
  • HIT B细胞启动子染色质可及性增强,启动子-转录起始位点区域H3K36me1沉积升高。

临床怎么用

  • Jmjd1c介导的表观遗传调控可能为HIT提供新的病理生理见解和潜在干预靶点。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Heparin-induced thrombocytopenia (HIT) is a common drug-induced immune disorder occurring in a subset of heparin-treated patients. Immune complexes comprising heparin, platelet factor 4 (PF4), and PF4/heparin-reactive antibodies are central to its pathogenesis. However, the role of epigenetic modification in HIT remains unexplored. Our study identified Jmjd1c, a member of the lysine-specific histone demethylase 3 subfamily, as an essential regulator of PF4/heparin-specific antibody production. Although Jmjd1c was expressed throughout B-cell development and was dispensable for normal B-cell development, its deficiency disrupted immune tolerance and promoted production of self-reactive antibodies in systemic autoimmune diseases, including PF4/heparin-specific platelet-activating antibodies, a hallmark of pathogenic HIT antibodies. Jmjd1c-deficient B cells were hyperresponsive, characterized by enhanced B-cell receptor (BCR)-induced proliferation. Transcriptomic analysis (RNA sequencing) revealed upregulation of pathways associated with BCR signaling, NF-κB activation, cell cycle, and systemic lupus erythematosus (SLE). CUT&Tag (cleavage under targets and tagmentation) profiling demonstrated that Jmjd1c deficiency increased H3K36me1 modification at gene start sites in these pathways, indicating that epigenetic dysregulation drives B-cell hyperactivation. Importantly, transcriptional profiling and regulon analysis of B cells from patients with HIT showed enrichment of BCR signaling, cell cycle, NF-κB, and SLE-associated pathways, closely mirroring those in Jmjd1c-deficient B cells. Epigenetic analyses further revealed enhanced promoter chromatin accessibility and elevated H3K36me1 deposition at promoter-transcription start site regions in HIT B cells. All these findings establish a strong molecular overlap between Jmjd1c deficiency and human HIT B cells and reveal a previously unrecognized epigenetic mechanism underlying HIT pathogenesis. To our knowledge, our study provides the first evidence linking epigenetic regulation to HIT, offering new insights into its pathophysiology.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Yu M, Zhou L, Zhang Y, et al. Jmjd1c-mediated epigenetic control of autoimmunity and HIT antibody production. Blood. 2026. PMID: 42095895. doi:10.1182/blood.2025029593

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。